ISRCTN15893334进行中（未招募）3 期
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP
Academic Medical Center (AMC)0 个研究点目标入组 96 人开始时间: 2018年2月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 96
研究概览
简要总结
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33608058/ protocol (added 22/02/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Probable or definite CIDP according to the EFNS/PNS criteria 2010 (all CIDP phenotypes)
- •2. Age = 18 years
- •3.1. Treatment naïve patients; or
- •3.2. Previously treated patients who have a relapse after a remission of at least 1 year; or
- •3.3. Patients treated with subjective or objective improvement after a single loading dose of IVIg in the last 3 months, and subsequent deterioration as judged by his or her treating physician.
排除标准
- •Current exclusion criteria as of 22/11/2022:
- •1. Presence of IgM paraproteinemia and/or anti-MAG antibodies or known CIDP-specific antibodies associated with poor treatment response to IVIg
- •2. Use of drugs known to cause a demyelinating neuropathy
- •3. Use of any immunosuppressive or immunomodulatory drugs in the previous 6 months (except for a single loading dose of IVIg within 3 months or low dose prednisolone (20 mg or less) for a short period not exceeding two weeks)
- •4. Known serious adverse events (SAEs) with previous IVIg or corticosteroid treatment. Hypersensitivity to methylprednisolone or any component of the formulation. Hypersensitivity to the human immunoglobulins or to any of the excipients. Selective IgA deficiency patients who developed antibodies to IgA
- •5. Systemic fungal infections, unless specific anti-infective therapy is employed
- •6. Known hyperprolinaemia type I or II or known fructose intolerance
- •7. One or more of the risk factors associated with increased risk of AEs of IVIg or IVMP or conditions that could lead to unblinding of treatment (i.e. diabetes; IgA deficiency; gastric ulcers; psychosis; severe hypertension (180/110 mmHg or more on repeated measurements); hypocalcaemia (lower than 2.20 mmol/L, corrected for albumin); moderate or severe heart failure; severe cardiovascular disease (i.e. more than one myocardial infarction and or ischemic stroke); renal failure (glomerular filtration rate < 30 ml/min)
- •8. History of osteoporosis or osteoporotic fractures
- •9. Known active malignancy, currently treated with chemotherapy or immunomodulatory drugs, or with a life expectancy of less than one year
- •10. Bodyweight more than 120 kg
- •11. Pregnancy or nursing mother; intention to become pregnant during the course of the study; female patients of childbearing potential either not using or not willing to use a medically reliable method of contraception for the entire duration of the study. A woman is considered of childbearing potential from menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Acceptable methods of contraception are: combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (whether oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (whether oral, injectable or implantable), progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap or diaphragm, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success)
- •12. Known cataract requiring surgery (previously: Known cataract or cataract obvious on fundoscopy)
- •13. Current psychosis or past history of psychosis
- •14. Poor dental status
- •15. Known pulmonary
研究者
相似试验
暂停
3 期
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial)10034606Chronic Inflammatory Demyelinating PolyneuropathyCIDPNL-OMON50340Academisch Medisch Centrum60
进行中（未招募）
1 期
Initial treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - combined immunoglobulin and steroid treatment versus immunoglobulin treatment alone.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)MedDRA version: 21.1Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-002511-34-GBAcademic Medical Centre, Amsterdam,96
进行中（未招募）
1 期
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial)Chronic inflammatory demyelinating polyneuropathy (CIDP)EUCTR2017-002511-34-NLAcademisch Medisch Centrum96
招募中
不适用
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDPNL-OMON21678Amsterdam UMC, location AMC96
已完成
3 期
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT00220740Grifols Therapeutics LLC117